AstraZeneca–HUTCHMED FDA Filing | Lucid Diligence Brief
This Lucid Diligence Brief explores AstraZeneca’s ORPATHYS and TAGRISSO FDA…
QC Healthcare–Sanguina Collaboration: Can Digital Biomarkers Scale? | Lucid Diligence Brief
This Lucid Diligence Brief examines the QC Healthcare–Sanguina digital…
Conavi Medical Raises C$10 Million in Public Offering | Lucid Diligence Brief
Conavi Medical’s C$10M Financing Puts Novasight U.S. Adoption and Funding…
SERB–Hansa Idefirix Deal | Lucid Diligence Brief
SERB’s Idefirix rights acquisition from Hansa Biopharma sharpens its rare…
GSK Acquires Nuvalent to Expand Oncology Pipeline | Lucid Diligence Brief
GSK strengthens its oncology portfolio with Nuvalent acquisition, adding…
Secretome STM-01 Duchenne Cardiomyopathy | Lucid Diligence Brief
Secretome’s STM-01 faces Duchenne cardiomyopathy endpoint, CMC, and regulatory…
Lucid Diligence Brief: AstraZeneca Camizestrant FDA Delay
Lucid Diligence Brief: AstraZeneca Camizestrant FDA Delay Raises SERENA-6…
Lucid Diligence Brief: SELLAS REGAL AML Phase 3 Nears Final Analysis
Lucid Diligence Brief: SELLAS approaches REGAL AML final analysis for…
Lucid Diligence Brief: Cullinan Therapeutics Gains FDA Orphan Drug Designation for CLN-049
Lucid Diligence Brief: Cullinan Therapeutics Receives FDA Orphan Drug…
Lucid Diligence Brief: Endologix's Pounce Acquisition
Lucid Diligence Brief: Endologix’s Pounce acquisition framed through clinical,…
Lucid Diligence Brief: NeuroVision’s Durin Life Sciences acquisition
Lucid Diligence Brief: NeuroVision’s Durin Life Sciences acquisition…
Lucid Diligence Brief: Axoft $55 million Series A
Lucid Diligence Brief: Axoft $55 million Series A Professional audiences only.…
